Last week, the cystic fibrosis community celebrated the approval of a new drug from Vertex (VRTX) Pharmaceuticals, a decision that offers the large majority of patients access to cutting-edge treatments.
Those treatments, however, don’t cover patients with certain rare mutations. And they are not cures for anyone.
Seeking to address those issues, the Cystic Fibrosis Foundation on Wednesday unveiled a $500 million initiative aimed at developing treatments for patients who aren’t helped by the Vertex drugs and, ultimately, at finding cures for all CF patients. The message is: Despite the success, there is still work to be done.